

August 2,2021

Supplementary Documents of Consolidated Financial Results for the First Three Months of the Year Ending March 31, 2022 (FY2021)



Stock code : 4886

ASKA Pharmaceutical Holdings Co., Ltd.

Statements of Income (Consolidated)

(Millions of yen) *The figures announced as ASKA Pharmaceutical Co., Ltd.

	*FY2020 Apr - Jun Actual	FY2021 Apr - Jun Actual	Actual +/-	Growth +/-
Net sales	13,714	14,221	+507	+3.7%
Operating profit	898	1,188	+290	+32.3%
Ordinary profit	987	1,329	+342	+34.7%
Profit attributable to owners of parent	739	1,098	+359	+48.6%

Major factors behind the increase in sales

- Steady growth in sales of main products such as THYRADIN, RIFXIMA, RELUMINA and FREWELL.
- Increase in demand for some generic drugs such as CANDESARTAN and LEUPRORELIN due to external factors.

Major factors behind the increase in profits

- Increase in gross profit by increasing the ratio of sales in brand-name drugs.

Net Sales by Business (Consolidated)

(Millions of yen)

*The figures announced as ASKA Pharmaceutical Co., Ltd.

	*FY2020 Apr - Jun	FY2021 Apr - Jun	Breakdown	Actual +/-	Growth +/-
Pharmaceutical drugs	12,609	12,840	90.3%	+231	+1.8%
Animal health drugs	1,091	1,351	9.5%	+259	+23.7%
Others	13	30	0.2%	+16	+130.0%
Total	13,714	14,221		+507	+3.7%

Sales of Main Products

(Millions of yen)

Area	Products	FY2020 Apr - Jun	FY2021 Apr - Jun		FY2021	
		Actual	Actual	YOY(%)	Forecast	YOY(%)
Internal Medicine	CANDESARTAN *1, *2	3,236	3,198	98.8%	10,605	86.0%
	THYRADIN	1,845	1,945	105.4%	7,279	101.0%
	RIFXIMA	1,118	1,247	111.5%	5,301	122.3%
	MERCAZOLE	361	381	105.5%	1,466	104.6%
	AMLODIPINE *1	337	291	86.4%	1,102	85.2%
Obstetrics and Gynecology	RELUMINA (2019.3~)	1,127	1,788	158.7%	7,257	127.1%
	FREWELL (2018.12~) *1	652	804	123.3%	2,655	89.9%
	ANGE	232	230	99.1%	1,016	111.9%
	Magsent (2020.3~) *3	236	226	95.8%	700	77.1%
	LUTEUM	94	152	161.7%	615	115.8%
Urology	LEUPRORELIN *1, *4	1,150	1,161	101.0%	3,919	87.1%

* 1 Generic drugs * 3 Total value of magnesium sulfate preparation


* 2 Including combination drugs * 4 1.88mg formulation is for gynecological indications only, but combined with 3.75mg formulation

Ratio of Sales in Brand-name Drugs


■ Brand-name drugs

■ Generic drugs

FY2020
Apr - Jun




FY2021
Apr - Jun



R&D Status

Transition of R&D expenses

(Millions of yen)



As of August, 2021

Development code (Generic name) Indication	Status
CDB-2914 (Ulipristal Acetate) Uterine fibroids	Filed
TAK-385 (Relugolix) Endometriosis	Filed
LF111 (Drospirenone) Contraception	Ph I / II
L-105 (Rifaximin) Hepatic encephalopathy (pediatrics)	Ph III
L-105 (Rifaximin) Crohn's disease	Ph I
AKP-009(Ludaterone Acetate) Benign Prostatic Hyperplasia	Ph II

*There are no changes from the previous announcement